Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Single-Payer Healthcare
  • Federal Workers’ Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

WHAT'S NEW

  • Single-Payer Healthcare
  • Federal Workers' Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Oct 16 2020

Full Issue

Major Players In Vaccine Supply Chain Warn Distribution Will Be Difficult

Whether making it, transporting it or administering it, every step of the COVID vaccination process is rife with complications, Stat reports.

Stat: Many Air Cargo Companies Are Unprepared To Transport Covid-19 Vaccines

As much of the world focuses on vaccine development to alleviate the pandemic, a new survey finds that just 28% of the air cargo companies that will play the highly crucial, behind-the-scenes role of transporting Covid-19 vaccines far and wide feel prepared for the job. At the same time, 19% of these companies report that they feel “very unprepared.” (Silverman, 10/15)

NPR: COVID-19 Vaccine Distribution Will Be Challenging. States Rush To Plan Ahead

Even the most effective, safest coronavirus vaccine won't work to curb the spread of the virus unless a large number of people get immunized. And getting a vaccine from the manufacturers all the way into people's arms requires complex logistics — and will take many months. Now, public health officers across the country are rushing to finish up the first draft of plans for how to distribute a coronavirus vaccine if and when it is authorized, and they're grappling with a host of unknowns as they try to design a system for getting the vaccine out to everyone who wants it. (Simmons-Duffin, 10/16)

The Hill: Bipartisan Governors Ask Trump For Help With COVID Vaccine Distribution Plan 

The bipartisan leaders of the National Governors Association on Thursday requested a meeting with President Trump to discuss "the roles and expectations of states" for the successful distribution of a COVID-19 vaccine. States are pleading with the Trump administration for more guidance on the logistics of a mass vaccination campaign, just one day before the deadline to submit draft distribution plans for a potential coronavirus vaccine. (Weixel, 10/15)

Atlanta Journal-Constitution: Georgia Faces Enormous Challenges To Distribute A COVID-19 Vaccine

While the fast-track development of a COVID-19 vaccine may seem like an enormous task, an even more daunting challenge may be getting approved vaccines into the arms of millions of people in Georgia and around the globe. (Oliviero and Yamanouchi, 10/15)

The Wall Street Journal: Pfizer, BioNTech Race To Meet Global Covid-19 Vaccine Needs 

The chief executive of the German company partnering with Pfizer Inc. in its coronavirus vaccine effort said the two are racing to increase production to meet the world’s needs, assuming the shot wins a regulatory green light. The two companies are now scrambling to scale up their manufacturing capacities, said Ugur Sahin, CEO of BioNTech SE. Both companies said they are confident they will be able to deliver all the doses they have already agreed to provide to governments, including the U.S. and the European Union. (Pancevski and Hopkins, 10/15)

In related vaccine news —

NPR: Drug Companies Use Tobacco Plant Protein As Ingredient In COVID-19 Vaccine

Historically, tobacco plants are responsible for their share of illness and death. Now they may help control the COVID-19 pandemic. Two biotech companies are using the tobacco plant, Nicotiana benthamiana, as bio-factories to produce a key protein from the coronavirus that can be used in a vaccine. (Palca, 10/15)

AP: Chinese Company Offers Coronavirus Vaccine To Students

A Chinese drug developer is offering an experimental coronavirus vaccine to students going abroad in a strategy health experts say raises safety and ethical concerns. China National Biotech Group has two vaccine candidates out of five from Chinese developers that are in the final stages of clinical trials. They are part of a global race to develop a vaccine that, if they are successful, offers the fledgling Chinese industry the potential for prestige and worldwide sales. (Wu, 10/15)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF